Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma

Capital Medical University

Status

Enrolling

Conditions

Neuroblastoma

Delayed Platelet Engraftment

Autologous Hematopoietic Stem Cell Transplantation

Treatments

Drug: Hetrombopag

Study type

Interventional

Funder types

Other

Identifiers

NCT06818916

[2024]-Y-002-D

Details and patient eligibility

About

The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is:

· Does drug hetrombopag promote platelet engraftment? Participants will take hetrombopag every day for 6 weeks or until platelet > 100*10^9/L.

Enrollment

30 estimated patients

Sex

All

Ages

Under 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age<18 years old;
Diagnosed as neuroblastoma;
ECOG ≤ 2;
First time receiving autologous hematopoietic stem cell transplantation;
The subjects or their legal guardians agree to participate and sign the informed consent form.

Exclusion criteria

ALT/AST > 3 ULN, or TBIL > 1.5 ULN;
Have experienced congestive heart failure, arrhythmia, peripheral arteriovenous thrombosis requiring medication treatment within one year prior to enrollment, or have experienced myocardial infarction or cerebral infarction within three months prior to enrollment;
Suffering from thromboembolic diseases;
Other situations that are not suitable for inclusion in the study determined by researchers.